Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03193619 |
Recruitment Status :
Enrolling by invitation
First Posted : June 21, 2017
Last Update Posted : December 8, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Peripheral Arterial Disease Peripheral Vascular Diseases Arterial Occlusive Diseases | Device: PTA (UltraScore Focused Force PTA Balloon) |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 350 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | A Prospective, Multi-Center, Single-Arm, Real-World Study Assessing the Clinical Use of the Bard® UltraScore™ Focused Force PTA Balloon |
Actual Study Start Date : | March 28, 2018 |
Actual Primary Completion Date : | October 29, 2020 |
Estimated Study Completion Date : | November 29, 2021 |
Group/Cohort | Intervention/treatment |
---|---|
PTA-UltraScore Focused Force PTA balloon
Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
|
Device: PTA (UltraScore Focused Force PTA Balloon)
Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough. The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated. |
- Achieve optimal PTA results [ Time Frame: Index procedure (Day 0); approximate duration of procedure is 90 minutes. ]Optimal result is defined as ≤30% residual stenosis without major flow-limiting dissection, as measured by angiographic imaging. Major flow limiting dissections are classified by the National Heart, Lung, and Blood Institute (NHLBI) as Grade D (Spiral luminal filling defects), Grade E (Appearance of new and persistent filling defects with reduced flow), and Grade F (Total occlusion without distal flow).
- Technical success of use of UltraScore™ Focused Force PTA balloon [ Time Frame: Index procedure (Day 0); approximate duration of procedure is 90 minutes. ]Technical success is determined subjectively by the investigator according to delivery location of the study device relative to the target lesion, as assessed by angiographic imaging, and inflation without movement.
- Rate of bail-out stenting due to dissection [ Time Frame: Index procedure (Day 0); approximate duration of procedure is 90 minutes. ]Rate of emergency artery stent placement for abrupt or threatened artery closure caused by arterial dissection immediately following index procedure.
- Freedom from target lesion revascularization (TLR). [ Time Frame: 30 days, 6 months, and 12 months post-index procedure ]TLR is defined as a revascularization procedure (e.g. PTA, stenting, surgical bypass, etc.) in target vessel after the index procedure
- Freedom from major amputation of the target limb [ Time Frame: 30 days, 6 months, and 12 months post-index procedure ]Major amputation is defined as above the ankle amputation
- Improved clinical measures from baseline [ Time Frame: 30 days, 6 months, and 12 months post-index procedure ]Resting ankle brachial index (ABI) and Rutherford classification for chronic limb ischemia measurements will be assessed clinically at follow-up and compared with baseline.
- Primary patency for Above the Knee (ATK) subjects [ Time Frame: 30 days, 6 months, and 12 months post-index procedure ]ATK subjects have a target lesion of the SFA or popliteal artery only. Primary patency is measured by duplex ultrasound (DUS) core lab; a peak systolic velocity ratio (PSVR) ≥2.5 suggests 50% restenosis and loss of patency.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
- Subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
- Subject must be willing to comply with the protocol requirements, including the follow-up procedures.
- Subject must have a target lesion (de novo lesion or prior failed treatment) that can be treated with the UltraScore™ Focused Force PTA balloon according to the Instructions for Use (IFU). Only a target lesion in the SFA, popliteal, or infra-popliteal arteries (posterior tibial, anterior tibial, or peroneal arteries) may be treated for this study.
- Subject must have an Above the Knee (ATK) or Below the Knee (BTK) target lesion with at least one vessel run-off.
- The target lesion must be able to be crossed using a guidewire (use of chronic total occlusion (CTO) or atherectomy is allowed).
Exclusion Criteria:
- Subjects that are to receive one or more stents as adjunctive therapy at the target lesion (bail out stenting is allowed).
- The subject has a single target lesion that involves both ATK and BTK arteries.
- The subject has a target lesion in a previously placed stent or stent graft (in-stent restenosis).
- The subject has a lesion, which in the opinion of the Investigator, would preclude safe use of the UltraScore™ Focused Force PTA balloon.
- The subject has a flow limiting dissection at the target lesion prior to use of the UltraScore™ Focused Force PTA balloon.
- The subject has acute limb ischemia.
- The subject has been assessed Rutherford category 6.
- The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.
- The subject has another medical condition or is currently participating in an investigational drug or another device study that, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03193619

Principal Investigator: | Craig Walker, MD | Cardiovascular Institute of the South (CIS) Clinical Research Corporation | |
Principal Investigator: | Robert Beasley, MD | Icahn School of Medicine at Mount Sinai | |
Principal Investigator: | Miguel Montero, MD | Baylor St. Luke's College of Medicine |
Responsible Party: | C. R. Bard |
ClinicalTrials.gov Identifier: | NCT03193619 |
Other Study ID Numbers: |
BPV-16-001 |
First Posted: | June 21, 2017 Key Record Dates |
Last Update Posted: | December 8, 2020 |
Last Verified: | December 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | Yes |
Vascular Diseases Peripheral Arterial Disease Peripheral Vascular Diseases Arterial Occlusive Diseases |
Cardiovascular Diseases Atherosclerosis Arteriosclerosis |